MX2022014160A - Composiciones de microbiota vaginal. - Google Patents

Composiciones de microbiota vaginal.

Info

Publication number
MX2022014160A
MX2022014160A MX2022014160A MX2022014160A MX2022014160A MX 2022014160 A MX2022014160 A MX 2022014160A MX 2022014160 A MX2022014160 A MX 2022014160A MX 2022014160 A MX2022014160 A MX 2022014160A MX 2022014160 A MX2022014160 A MX 2022014160A
Authority
MX
Mexico
Prior art keywords
vaginal microbiota
lactobacillus
compositions
microbiota compositions
bacteria
Prior art date
Application number
MX2022014160A
Other languages
English (en)
Inventor
Kenneth F Blount
Dana M Walsh
Heidi Hau
Kristi Strandberg
Lee A Jones
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2022014160A publication Critical patent/MX2022014160A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se describen composiciones y métodos para el tratamiento de pacientes. Una composición de ejemplo puede incluir una composición de microbiota vaginal. La composición de microbiota vaginal puede incluir una mezcla de bacterias. La mezcla de bacterias puede incluir Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus jensenii y Lactobacillus rhamnosus.
MX2022014160A 2020-06-01 2021-06-01 Composiciones de microbiota vaginal. MX2022014160A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063033008P 2020-06-01 2020-06-01
PCT/US2021/035245 WO2021247571A1 (en) 2020-06-01 2021-06-01 Vaginal microbiota compositions

Publications (1)

Publication Number Publication Date
MX2022014160A true MX2022014160A (es) 2022-11-30

Family

ID=76601828

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014160A MX2022014160A (es) 2020-06-01 2021-06-01 Composiciones de microbiota vaginal.

Country Status (10)

Country Link
US (1) US20230201281A1 (es)
EP (1) EP4157298A1 (es)
JP (1) JP2023527876A (es)
KR (1) KR20230018389A (es)
CN (1) CN115768451A (es)
AU (1) AU2021284269A1 (es)
BR (1) BR112022024128A2 (es)
CA (1) CA3179613A1 (es)
MX (1) MX2022014160A (es)
WO (1) WO2021247571A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114990099A (zh) 2015-05-11 2022-09-02 迈彼欧提克斯制药有限公司 用于使益生菌在使细菌于肠道中定植用途的固体颗粒上生长成益生菌生物膜的系统和方法
EP3463403A4 (en) 2016-05-25 2020-04-15 Mybiotics Pharma Ltd COMPOSITION AND METHODS FOR TREATMENT WITH A MICROBIOTE
WO2024072421A1 (en) * 2022-09-30 2024-04-04 Bonafide Health, Llc Probiotic and folic acid compositions and methods of using
CN117535207A (zh) * 2024-01-04 2024-02-09 四川厌氧生物科技有限责任公司 一种格氏乳杆菌及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3181684B1 (en) 2010-02-01 2019-05-29 Rebiotix Inc. Bacteriotherapy for clostridium difficile colitis
EP2428214A1 (en) * 2010-09-14 2012-03-14 HSO Health Care GmbH Compositions for the vaginal and oral administration of lactobacillus and uses thereof
JP6330032B2 (ja) 2013-06-05 2018-05-23 レビオティクス インコーポレイテッドＲｅｂｉｏｔｉｘ，Ｉｎｃ． 微生物叢回復療法組成物を製造、処理、および梱包するための方法
BR112016026654A2 (pt) * 2014-05-16 2017-08-15 Pizeta Group Srl Composições contendo ácido bórico e uma mistura de lactobacillus
ES2889902T3 (es) 2015-06-09 2022-01-14 Rebiotix Inc Métodos de fabricación de composiciones para terapia de restauración de la microbiota (TRM)
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
WO2017001440A1 (en) * 2015-06-29 2017-01-05 Ferring B.V. Lactobacillus rhamnosus bacterium for treatment of e.g. bacterial vaginosis
WO2018013583A2 (en) * 2016-07-11 2018-01-18 The Brigham And Women's Hospital, Inc. Medicinal vaginal lactobacillus cocktail

Also Published As

Publication number Publication date
CN115768451A (zh) 2023-03-07
JP2023527876A (ja) 2023-06-30
WO2021247571A1 (en) 2021-12-09
BR112022024128A2 (pt) 2022-12-27
AU2021284269A1 (en) 2023-01-05
EP4157298A1 (en) 2023-04-05
CA3179613A1 (en) 2021-12-09
US20230201281A1 (en) 2023-06-29
KR20230018389A (ko) 2023-02-07

Similar Documents

Publication Publication Date Title
MX2022014160A (es) Composiciones de microbiota vaginal.
WO2018013583A3 (en) Medicinal vaginal lactobacillus cocktail
MX2018012781A (es) Nuevo uso medico para los probioticos.
D'Ercole et al. Implants with internal hexagon and conical implant-abutment connections: an in vitro study of the bacterial contamination
MX2020002727A (es) Nuevo uso para tratamiento de infecciones por clostridium difficile.
BR112022004569A2 (pt) Cepas bacterianas, suas composições e seu uso para o tratamento de distúrbios gastrointestinais
MX2020003198A (es) Bacterias acidolácticas novedosas y uso de las mismas.
IN2013MN00601A (es)
BRPI0519086A2 (pt) bactÉria gram-positiva, nço invasiva, nço patogÊnica, vetor de dna, mÉtodo para a produÇço heteràloga de polissacarÍdeos capsulares complexos (cps) em uma bactÉria gram-positiva, nço invasiva, nço patogÊnica, e, composiÇço farmaceuticamente aceitÁvel
Reed et al. Strain-dependent inhibition of Clostridioides difficile by commensal Clostridia carrying the bile acid-inducible (bai) operon
Duar et al. Identification and characterization of intestinal lactobacilli strains capable of degrading immunotoxic peptides present in gluten
HK1067985A1 (en) Lactic acid bacteria and their use for treating and preventing cancer
MX2021012041A (es) Metodos para promover la diferenciacion de celulas epiteliales timicas y progenitores de celulas epiteliales timicas de celulas madre pluripotentes, celulas resultantes y usos de estas.
KR102452792B1 (ko) 고창을 감소시키기 위한 조성물 및 방법
AU2002257966A1 (en) Immunostimulatory agent comprising a biomass of methanotrophic bacterium
MX2010002867A (es) Cepas de micoplasma atenuadas vivas.
US20180344783A1 (en) Natural intra-vaginal inserts to control imbalanced ph
MX2022008789A (es) Composiciones y métodos para controlar los microbios indeseables y mejorar la salud animal.
GB0421448D0 (en) A method for producing metabolically active micro organisms
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2022001973A (es) Formulaciones para la prevención o reducción de infecciones por c. difficile.
Daniele et al. Curative effect of the probiotic strain Lactobacillus fermentum L23 in a murine model of vaginal infection by Gardnerella vaginalis
WO2020091180A3 (ko) 프로바이오틱스를 유효 성분으로 포함하는 이차성 골다공증의 예방 또는 치료용 조성물
EP3932416A4 (en) COMPOSITION FOR IMPROVEMENT, PREVENTION OR TREATMENT OF BONE DISEASES OR METABOLIC DISEASES, INCLUDING NEW LACTOBACILLUS SAKEI CVL-001 STRAIN AND CULTURE MEDIUM THEREOF
MX2020013857A (es) Bacterias bifidobacterium bifidum no viables y usos de las mismas.